0DPB.LSE Bavarian Nordic A/S
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is 0DPB.LSE undervalued?
Graham numberThe Graham number of Bavarian Nordic A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bavarian Nordic A/S fundamental analysis
No fundamental analysis for Bavarian Nordic A/S yet.
Bavarian Nordic A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN …
Full company profileBavarian Nordic A/S financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bavarian Nordic A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.01B | 1.37B | 501M | 662M | 1.85B | - | - | - |
| Gross Profit | 709M | 1.08B | 246M | 308M | 673M | - | - | - |
| Operating Income | 33.0M | 353M | -354M | -328M | 380M | - | - | - |
| Net Income | 30.6M | 181M | -362M | -347M | 278M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 2.82B | 3.15B | 3.06B | 7.05B | 8.76B | - | - | - |
| Total Liabilities | 806M | 646M | 880M | 5.18B | 3.86B | - | - | - |
| Shareholders' Equity | 2.02B | 2.51B | 2.18B | 1.87B | 4.89B | - | - | - |
| Cash & Short-term Investments | 1.90B | 2.58B | 2.32B | 472M | 1.67B | - | - | - |
| Total Debt | 29.7M | 400M | 398M | 3.13B | 2.91B | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 268M | 216M | -289M | -276M | 572M | -359M | 220M | - |
| Capital Expenditure | 91.5M | 78.7M | 202M | 360M | 223M | 483M | 361M | 0.00 |
| Ratios | ||||||||
| ROE | 1.5% | 7.2% | -16.6% | -18.6% | 5.7% | - | - | - |
| ROA | 1.1% | 5.8% | -11.8% | -4.9% | 3.2% | - | - | - |
| Net Profit Margin | 3.0% | 13.2% | -72.3% | -52.3% | 15.0% | - | - | - |
| Debt to Equity | 0.01x | 0.16x | 0.18x | 1.68x | 0.60x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bavarian Nordic A/S dividends
Bavarian Nordic A/S has not paid dividends in the last 9 fiscal years.
Last stock split: 694:549 on Mar 10, 2020.
Who owns Bavarian Nordic A/S
- Insiders 0.01%
- Institutions 35.92%
- Public & others 64.06%
- Free float 75.6M
Bavarian Nordic A/S company profile
- Company name
- Bavarian Nordic A/S
- Ticker
- 0DPB.LSE
- ISIN
- DK0015998017
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 1,906
- Fiscal year end
- December
- Address
- Philip Heymans Alle 3, Hellerup, Denmark, 2900
- Phone
- 45 33 26 83 83
- Website
- bavarian-nordic.com
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Bavarian Nordic A/S management
5- Mr. Henrik Juuel M.Sc.CFO & Executive VP · born 1965
- Ms. Tarja StenvallPresident & CEO
- Mr. Russell Thirsk M.Sc.Executive VP & COO · born 1968
- Ms. Nicole SeroffVice President Corporate Communications
- Mr. Jean-Christophe May M.B.A., Pharm.D.Executive VP & Chief Commercial Officer · born 1967